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Abstract 
The Tip60 and E2F1 proteins are key players of the cellular response induced by genotoxic 
stresses. Here, new insights into the involvement of both proteins during the DNA damage 
response are provided. We show that Tip60 interacts with E2F1 and promotes its acetylation. 
We identify the Lysine residues 120/125 of the E2F1 protein as the prime target sites of Tip60 
and show that acetylation at these sites promotes the accumulation of E2F1. Importantly, we 
demonstrate that cisplatin induces the accumulation of E2F1 in a Tip60-dependent manner. 
However, and in contrast to PCAF and p300, Tip60 is not required for the induction of 
apoptosis in cisplatin-treated cells. Instead, Tip60 and E2F1 are involved in the upregulation 
of the Excision Repair Cross-Complementation group 1 (ERCC1) protein expression, an 
enzyme involved in the repair of cisplatin-induced DNA lesions. These findings identify 
Tip60 as a direct regulator of E2F1 and support their cooperative role in DNA repair. 
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Introduction 
 Tip60 is a member of the MYST family of HAT and was originally identified as a 
HIV-1 Tat interactive protein [1]. Tip60 acetylates core histones and modulates chromatin 
structure, influences gene transcription and contributes to the DNA damage response [2]. 
Tip60 also catalyzes acetylation of non-histone proteins involved in transcription control and 
activation of DNA damage checkpoint pathways [3]. Acetylation of p53 by Tip60 plays a 
critical role in the p53-dependent apoptotic response following DNA damage [4,5]. Tip60’s 
acetyltransferase activity is also rapidly activated by ionizing radiation and this contributes to 
the acetylation and activation of the Ataxia Telangiectasia Mutant (ATM) protein kinase and 
further phosphorylation of p53 and Chk2 [6]. Therefore through its ability to acetylate 
proteins, Tip60 is a key actor of the DNA damage response. 
 Mounting evidence also implicates the transcription factor E2F1 as an important 
component of the DNA damage response. E2F1 protein is phosphorylated and stabilized by 
ATM/ATR and Chk2 kinases ([7-10], both of which are integral components of the DNA 
damage signalling pathway. The high level of E2F1 protein allows the binding and activation 
of a different spectrum of genes involved in the induction of apoptosis such as Apaf-1, ARF, 
Chk1, ATM and p73 (for review[10]). E2F1 may have an additional role in replication control 
and DNA repair. Indeed, it is becoming apparent that E2F1 co-localizes and/or interacts with 
the MRN checkpoint protein complex [11] as well as with TopBP1 and the BRCA1-repair 
complex [12] in response to DNA damage. Furthermore, recent studies demonstrate that E2F1 
contributes to UV-induced Nucleotide Excision Repair (NER) by promoting accessibility of 
NER factors to sites of damage [13,14]. 
In response to genotoxic stress, E2F1 is stabilized through post-transcriptional 
modifications and it has been shown that acetylation can induce an E2F1-dependent apoptotic 
response in damaged cells [15]. Although the p300 and P/CAF HATs have been involved in 
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E2F1 acetylation and accumulation following exposure to some DNA damaging agents 
[15,16], the role of the Tip60 HAT has never been investigated. In this study, we demonstrate 
that Tip60 acetylates the E2F1 protein and promotes its accumulation in response to cisplatin. 
Importantly, such accumulation does not trigger apoptosis. Instead, the Tip60/E2F1 complex 
promotes the accumulation of the Excision Repair Cross-Complementation group 1 (ERCC1) 
enzyme. These data point to a new aspect of E2F1 and Tip60 function in DNA repair. 
 
Material and methods 
Cell culture, transfection and treatments 
H358 and H69 human lung carcinoma cell lines and SAOS2 osteosarcoma cells were cultured 
as described [17,18]. H69 cells express high level of E2F1 and Tip60, H358 cells express 
moderate level of both proteins and SAOS2 cells express very low level of E2F1 and Tip60. 
Transient transfection experiments of plasmids were carried out using Fugene 6 (Roche 
Diagnostic) according to manufacturer’s instructions. The amounts of expression vectors were 
normalized with the corresponding empty vectors. Cells were harvested 24 or 48h post-
transfection. pcDNA3-HA-tagged Tip60, pcDNA3-HA-tagged Tip60G380 and production of 
His-Tip were previously described [18]. pcDNA3-E2F1 was a gift from D.Trouche. E2F1 
truncated mutants pGEX-E2F11-191 and pGEX-E2F11-284 were a gift from K. Helin, pGEX-
E2F141-108 and pGEX-E2F141-127 from W. Krek  and pGEX-E2F11-120 and pGEX-E2F189-191 
from M. Giacca. Transfection of siRNA was carried out using oligofectamine (Invitrogen) 
according to manufacturer’s instructions. The siRNAs used were as follow : Tip60 forward 
5’-AUAGUACAGUGUCUUAUGGUCAAGG-3’ and reverse 5’-
CCUUGACCAUAAGACACUGUACUAU-3’; p300 forward 5’-
CAGAGCAGUCCUGGAUUAG-3’ and reverse 5’-CUAAUCCAGGACUGCUCUG-3’. 
siRNA against PCAF were purchased from invitrogen (PCAF StealthTMRNAi). For all 
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experiments, the siRNA oligonucleotide duplex used as control was 5’-
UCGGCUCUUACGCAUUCAA-3’. The cells were analyzed 72h post-transfection. For 
experiments with cisplatin, cells were transfected for 72h with siRNAs and Cisplatin 
(Calbiochem) (50µM) was added for the indicated time. For the study of E2F1 acetylation, 
cells were incubated with TSA (Sigma Aldrich) (100ng/ml) for 18h before lysis. 
 
In vitro translations and pull-down assays 
In vitro translation and pull-down assays were performed essentially as described previously 
using beads coated either with GST or GST-E2F1 fusion proteins and equivalent amounts of 
in vitro-translated wild-type Tip60 protein [19]. 
 
In vitro acetylation assays and site-directed mutagenesis 
In vitro acetylation assays were performed as described previously using GST and a panel of 
E2F1 GST fusion fragments spanning the full length protein and equivalent amounts of 
recombinant His-tagged Tip60212-513 [18]. Site-directed mutagenesis was carried out with the 
QuickChange II Site-directed Mutagenesis Kit (Stratagene) using pGST-E2F1 and 
pcDNA3.1-E2F1 as templates. Mutation was confirmed by DNA sequencing. 
 
Immunoblotting and immunoprecipitation 
Immunoblotting was performed by using whole cell extracts prepared in RIPA buffer. For 
immunoprecipitation of acetylated E2F1, TSA (100ng/ml) was added to RIPA buffer and 500 
µg of proteins were used. For co-immunoprecipitation experiments from transient 
transfections, cells were lysed in TNE buffer (150mM NaCl, 50mM Tris pH 7.4, 0,5% NP40, 
1% Triton X-100, 1mM EDTA, 1mM EGTA) supplemented with protease inhibitors and 
processed as described previously [18]. For co-precipitation of endogenous proteins, nuclear 
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extracts were prepared by lysing the cells in 5 volumes of pre-cold hypotonic buffer (10mM 
Tris-HCl pH 7,5, 10mM KCl, 1,5mM MgCl2, and 0,5mM DTT) supplemented with 1% NP40 
for 10 min on ice. Nuclei were pelleted by centrifugation for 15 min at 3000 rpm and lysed in 
a buffer containing 150mM NaCl, 50mM Tris pH 7.4, 0.5% NP40, 1% Triton X-100, 1mM 
EDTA, 1mM EGTA, supplemented with protease inhibitors. Three milligrams of nuclear 
extracts were subjected to immunoprecipitation with anti-E2F1 antibody. The antibodies used 
are as follows: anti-Ha (HA-11; Covance), anti-E2F1 (KH95; BD Pharmingen, C20; Santa 
Cruz), anti-acetylated lysine (Cell Signaling), anti-ERCC1 (FL-297, Santa Cruz), anti-PCAF 
(E8, Santa Cruz), anti-p300 (N-15, Santa Cruz) and anti-actin (A2066, Sigma).  
 
Quantitative RT-PCR and RT-PCR analyses 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and subjected to quantitative RT-
PCR as previously described [20]. The specific primers used for mRNA amplification were as 
follows: Tip60 forward: 5’-AGGGCACCATCTCCTTCTTT-3’; Tip60 reverse: 5’-
GTTAGGATGCAGGCCACATT-3’; E2F1 forward: 5’-
AGACCCTGCAGAGCAGATGGTTAT-3’; E2F1 reverse: 5’-
TCGATCGGGCCTTGTTTGCTCTTA-3’; ERCC1 forward: 5’-
TGTCCAGGTGGATGTGAAAG-3’; ERCC1 reverse: 5’-AGGATCAATGTGCAGTCGG-
3’; GAPDH forward: 5’-GCAGATCCCTCCAAAATCAA-3’; GAPDH reverse: 5’-
ATCCACAGTCTTCTGGGTGG-3’.  
 
Apoptosis analysis  
Apoptosis was studied on a total cell population using the PE-conjugated monoclonal active 
caspase3 antibody apoptosis kit (BD Pharmingen) according to the manufacturer’s protocol. 
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Stained cells were analysed by flow cytometric analysis using a FACScan flow cytometer 
(BD Biosciences).  
 
Results 
Endogenous E2F1 protein binds to Tip60 
 It had been previously shown that overexpressed Tip60 and E2F1 proteins are able to 
form a complex [21]. Therefore, we examined whether both proteins could also interact in our 
cells. H358 lung adenocarcinoma cells were cotransfected with HA-Tagged Tip60 and/or 
E2F1 expression vectors and coimmunoprecipitation experiment was performed using anti-
E2F1 antibody. Immunoblotting with anti-HA antibody showed that Tip60 is present in E2F1 
immunoprecipitates confirming that exogenous Tip60 and E2F1 proteins interact (Figure 1A). 
To investigate the existence of a Tip60/E2F1 complex at a more physiological level, co-
immunoprecipitation experiments were conducted in nuclear extracts of H69 small cell lung 
carcinoma cells that express high level of both proteins. Endogenous Tip60 was detected in 
E2F1 immunoprecipitates, but not in immunoprecipitates obtained with a control IgG 
antibody (Figure 1B). Finally,  to determine whether Tip60 interacts directly with E2F1, in 
vitro binding experiments were carried out. Figure 1C showed that « in vitro » translated 
Tip60 binds to GST-E2F1 but not to GST alone. We conclude from these data that E2F1 is a 
direct Tip60 binding partner.                                                                                                                               
 
Tip60 acetylates E2F1 at lysines 120/125 
 E2F1 has been reported to recruit Tip60 (and other members of the Tip60 complex) to 
target chromatin in vivo [21]. However, the ability of Tip60 to acetylate E2F1 has never been 
investigated although it has been demonstrated that the E2F1 protein is acetylated by the 
p300/CBP and P/CAF HATs [22]. To analyse if E2F1 was acetylated by Tip60 in vivo, we 
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transfected H358 cells with HA-Tip60 expression vector. An anti-acetylated lysine antibody 
was then used to precipitate endogenous acetylated E2F1 which was detected by western 
blotting using anti-E2F1 antibody. The data showed that the level of acetylated E2F1 
increases in cells transfected with HA-Tip60 compared to cells transfected with a control 
plasmid (Figure 2A). Similar results were obtained when immunoprecipitation was performed 
with anti-E2F1 antibody followed by immunoblotting with anti-acetylated lysine antibody 
(Figure 2B). Interestingly, we noticed that the level of the E2F1 protein increases in the 
presence of Tip60. On the other hand the anti-acetylated lysine antibody precipitated less 
E2F1 in cells depleted for Tip60 by the use of specific siRNA compared to cells transfected 
with control siRNA (Figure 2C). Together, these results indicate that Tip60 acetylates E2F1 
in vivo. To go further, we wanted to identify the lysines modified by Tip60 on the E2F1 
protein. Using in vitro acetyltransferase assays (HAT) with C14-Acetyl-CoA and a series of 
E2F1-GST fusion fragments spanning the full length E2F1 protein, we demonstrated that 
recombinant Tip60 acetylates the N-terminal half of E2F1(89-284) in a region restricted to 
amino acids 109 to 127 (Figures 3A and B). As a cluster of three lysines resides in this region, 
we then generated a series of mutant proteins in which two out of the three lysine residues 
were mutated to arginine, an amino acid resistant to acetylation. Acetylation of these mutants 
by recombinant Tip60 was then tested using in vitro HAT assays. As shown in Figure 3C, 
arginine substitution at lysines 120/125 (K120/125R) abolished E2F1 acetylation whereas 
mutating the 117/120 (K117/120R) or 117/125 (K117/125R) residues resulted in a reduced 
capacity of Tip60-mediated acetylation. Therefore, these results indicate that lysines 120 and 
125 are the prime-candidate sites for Tip60 acetylation. To confirm these data, we tested 
whether the K120/125R E2F1 mutant was defective for acetylation by Tip60 in vivo. SAOS2 
cells that express very low level of endogenous E2F1 were transfected with HA-Tip60 along 
with wild type E2F1 or mutant K120/125R E2F1 expression vectors. Anti-acetylated lysine 
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antibody was used to precipitate the E2F1 or the K120/125R E2F1 protein which was 
detected by immunoblotting using anti-E2F1 antibody. As expected, only the wild type form 
of E2F1 was precipitated (Figure 3D). Overall, these data demonstrate that Tip60 acetylates 
E2F1 on its lysines residues 120/125. 
 
Acetylation by Tip60 stabilizes E2F1 protein 
 Because we had observed that the expression level of E2F1 was modified when Tip60 
was expressed (Figure 2B), we postulated that Tip60 could control E2F1 expression. 
Transfection of HA-Tip60 in H358 cells resulted in a significant increase of the E2F1 protein 
level (Figure 4A). On the other hand, depriving cells of Tip60 using siRNAs diminished the 
expression of the E2F1 protein (Figure 4B). In both experiments, the E2F1 transcripts were 
not significantly affected by Tip60 as measured by quantitative PCR (Supplementary Fig1). 
To test whether E2F1 accumulation occurred as a result of Tip60-dependent acetylation, we 
used a mutant Tip60 (Tip60G380) with impaired HAT activity [23]. H358 cells were 
transfected with HA-Tip60 or HA-Tip60G380 and western blots experiments were 
performed. As compared to wild type Tip60 whose transfection clearly increased the level of 
E2F1, the Tip60 mutant did not have a significant effect on E2F1 expression (Figure 4C) 
although it was expressed at levels equal to wild type Tip60, and as still able to interact with 
E2F1 (Figure 4D). These data support the fact that Tip60 HAT activity is required for the 
accumulation of the E2F1 protein. In that case, expression of the E2F1-K120/125R mutant 
might not change in the presence of Tip60. To confirm this, SAOS2 cells were co-transfected 
with HA-Tip60 and/or WT E2F1 or mutant E2F1-K120/125R and immunoblotting was 
carried out with anti-E2F1 antibody. As expected, expression of mutant E2F1-K120/125R did 
not vary in the presence of Tip60 whereas expression of WT E2F1 was upregulated (Figure 
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4E). Collectively, these results show that acetylation by Tip60 on lysine residues 120/125 
stabilizes the E2F1 protein. 
 
The Tip60/E2F1 complex controls ERCC1 accumulation in response to cisplatin 
 Both Tip60 and E2F1 play active roles in the cellular response induced by genotoxic 
agents [3 ,5,10,15,24]. It has been reported that E2F1 is stabilized by radiations and DNA 
damaging agents [9,25]. Furthermore, acetylation by PCAF and to a lesser extend by p300 
promotes the accumulation of E2F1 [22,26], and PCAF-dependent acetylation of E2F1 is 
important in activating pro-apoptotic genes following doxorubicin exposure [15]. These data 
prompted us to examine whether regulation of E2F1 by Tip60 could play a role in the 
response to genotoxic stress. Platinum-based chemotherapy is commonly used for the 
treatment of lung cancer. Treating with cisplatin the H358 cellular model that derives from a 
lung adenocarcinoma induced a time-dependent upregulation of the E2F1 protein (Figure 5A) 
but did not change the level of the E2F1 transcripts (Supplementary Fig2). In these 
conditions, apoptosis was observed after 24 hours of cisplatin treatment (Figure 5B). 
Abrogation of PCAF expression by specific siRNA in H358 cells exposed for 24 hours to 
cisplatin prevented E2F1 accumulation (Figure 5C) as well as apoptosis (Figure 5D). This 
was in agreement with the role of PCAF in the stimulation of the E2F1-dependent apoptotic 
response following genotoxic stress [15], in that case cisplatin. In the same conditions of 
cisplatin treatment, a less significant effect on E2F1 expression and apoptosis was observed 
when expression of p300 was abolished using specific siRNA (Supplementary Fig3). In 
contrast, the neutralisation of Tip60 using siRNA did not affect apoptosis in cells exposed for 
24h to cisplatin (Figure 5D), although it was able to prevent E2F1 accumulation (Figure 5E). 
These data therefore demonstrate that Tip60 is implicated in the stabilisation of E2F1 
expression in response to DNA damage but is not required for apoptosis occurrence. E2F1 
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was recently involved in DNA repair [13]. Interestingly, we observed that Tip60 was 
important for the accumulation of E2F1 soon after cisplatin exposure and before apoptosis 
takes place (Figure 5F). These data suggested that a Tip60/E2F1 crosstalk acts at the early 
times of the DNA damage response. 
 Cisplatin forms DNA adducts leading to intrastrand or interstrand cross-links which 
disrupt the structure of the DNA molecule. The excision repair cross-complementation group1 
(ERCC1) enzyme plays a rate-limiting role in the repair of platinum-DNA adducts [27-29]. 
Increased levels of the ERCC1 protein were observed when H358 cells were exposed to 
cisplatin (Figure 6A). Interestingly, we noticed that ERCC1 upregulation correlates with 
E2F1 accumulation (Figure 5A). Based on these data we postulated that the Tip60/E2F1 cross 
talk could control ERCC1 accumulation following cisplatin exposure. To respond, H358 cells 
were first transfected with siRNA against Tip60 and exposed for 2 hours to cisplatin. Beside 
its repressive effect on E2F1 expression, the neutralisation Tip60 expression also prevented 
the accumulation of ERCC1 expression induced by cisplatin (Figure 6B). In the same 
conditions, the abrogation of PCAF or p300 expression did not significantly affect ERCC1 
expression (Supplementary Fig4). To confirm the direct involvement of Tip60 in the control 
of ERCC1 expression, we investigated the impact of Tip60 overexpression on ERCC1 protein 
expression level in cells exposed or not to cisplatin for 2 hours. The data showed an increase 
of the ERCC1 protein level in cells transfected with HA-Tip60 and treated with cisplatin, as 
expected (Figure 6C). To evaluate the role of E2F1 in the Tip60-dependent control of ERCC1 
expression, SAOS2 cells were transfected with plasmids encoding wild type or K120/125R 
mutant E2F1, and protein extracts were subjected to western blotting with an anti-ERCC1 
antibody. Overexpression of wild type E2F1 induced an accumulation of the ERCC1 protein 
compared to cells transfected with an empty vector, whereas no significant effect was 
observed with the E2F1-K120/125R mutant (Figure 6D). Together, these data strongly 
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suggested that a Tip60/E2F1 crosstalk controls ERCC1 accumulation in response to cisplatin. 
Of note, no significant variation of the ERCC1 transcript was observed following cisplatin 
exposure or when H358 cells were transfected with siRNA against Tip60 or with the wild 
type or mutant E2F1 expression vector (Supplementary Fig5), suggesting that post-
transcriptional modifications account for variation of ERCC1 protein expression level in these 
conditions. 
 
Discussion 
 DNA damage and repair mechanisms are a subject of intense investigations. They 
constitute major defenses for the maintenance of genomic stability and play a key role in the 
successful treatment of cancer. E2F1 and Tip60 are multi-functional damage responsive 
proteins. Recently, their involvement in the repair of DNA lesions has also emerged. In this 
study, we demonstrate a direct link between the E2F1 and Tip60 proteins, and provide data 
that support a role of the E2F1/Tip60 complex in the control of key regulators of DNA repair 
mechanisms.  
 Earlier studies have unravelled acetylation as an important post-translational 
modification of the E2F1 transcription factor during the DNA damage response. In this 
respect, the p300/CBP and PCAF acetyltransferases are key regulators of E2F1 activity as 
they promote its stabilization through reversible acetylation at lysines residues 117/120/125 
[22,26]. Acetylation at these sites specifically activates the DNA binding activity and 
transactivation potential of E2F1, and modifies the target promoter selection, preferentially 
boosting E2F-driven transcription of pro-apoptotic genes after doxorubicin treatment [15]. In 
this study, we demonstrate that E2F1 is also acetylated and stabilized by the Tip60 
acetyltransferase and show that E2F1 accumulates in a Tip60-dependent manner after DNA 
damage. Surprisingly, we provide evidence that the lysine residues 120/125 of E2F1 are also 
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the prime target sites of Tip60 HAT activity. However, and in contrast to the PCAF 
acetyltransferase, acetylation/accumulation of E2F1 by Tip60 does not promote an E2F1-
dependent apoptotic program but induces the accumulation of the Excision Repair Cross-
Complementation group1 (ERCC1) protein after cisplatin exposure. Of note and also in 
contrast to PCAF, acetylation by Tip60 does not modify the DNA binding activity of E2F1 
(data not shown). Altogether, these results support the idea that E2F1 acetylation favors either 
DNA repair or apoptosis depending on the selected HAT. Alternatively, we cannot exclude 
the possibility that DNA damaging agents could first induce the acetylation of E2F1K120/125 
by Tip60 to promote DNA repair, and then stimulate subsequent E2F1K117 acetylation by 
P/CAF to induce apoptosis if DNA lesions cannot be repaired.  
 Nucleotide Excision Repair (NER) is a highly conserved DNA repair pathway that 
repairs DNA lesions induced by cisplatin. ERCC1 is a critical gene within the NER pathway 
through its ability to excise the damaged portion of the DNA [30]. Overexpression of ERCC1 
is associated with the repair of cisplatin-induced DNA damage and the clinical resistance to 
platinum-chemotherapy, especially in non-small cell lung cancer patients [31,32]. A recent 
report in non treated prostate cancer cells shows that Tip60 controls the expression of several 
DNA repair genes including ERCC1 [33]. In this study, we demonstrate that Tip60 is 
absolutely required for the accumulation of the ERCC1 protein induced by cisplatin 
treatment, thereby highlighting Tip60 as an critical regulator of DNA repair genes. 
Furthermore, we provide some data that strongly support the notion that a Tip60/E2F1 cross 
talk is important for the accumulation ERCC1 in response to cisplatin. Together, these results 
fit well with previous studies identifying a direct correlation between cisplatin resistance and 
expression of E2F1 [34] and Tip60 [33] in tumor cell lines. Very recently, expression of E2F1 
was shown to enhance NER following UV exposure [13]. Our results add further support to a 
critical role of E2F1 in the repair of bulky DNA lesions. Interestingly, we show that Tip60 
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does not modulate the level of ERCC1 transcripts in H358 cells exposed to cisplatin. 
Therefore these results demonstrate a non-transcriptional role of the Tip60/E2F1 complex on 
ERCC1 expression and suggest that post-transcriptional modifications account for regulation 
of ERCC1 expression. Further experiments are now needed to characterize the molecular 
mechanisms that control the expression of the ERCC1 protein in that case.  
 It was previously reported that the Tip60 HAT complex is recruited to E2F1-target 
genes and contributes to histone acetylation in response to mitogenic signals [21]. In this 
study, we demonstrate a functional link between E2F1 and Tip60 during the process of DNA 
repair. Therefore, it is tempting to speculate that Tip60 could act in physiological conditions 
as a transcriptional cofactor of E2F1 to drive the expression of cell cycle target genes. In a 
context of genotoxic stress, the Tip60/E2F1 complex could behave as a sensor of DNA 
damage and regulate the expression of genes involved in DNA repair. The Tip60/E2F1 
complex could thus facilitate cell cycle progression while guaranteeing genome stability.  
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Figure legends 
Fig. 1. Endogenous E2F1 interacts with Tip60 
H358 cells were cotransfected with pcDNA3-E2F1 and/or pcDNA3-HA-Tip60 expression 
vectors. Whole cell extracts were immunoprecipitated with anti-E2F1 antibody and 
immunoblotted with anti-HA or anti-E2F1 antibody. Irrelevant IgG was used as a negative 
control for immunoprecipitation. Actin was used as a loading control for western blotting. (B) 
Endogenous E2F1 was immunoprecipitated from H69 nuclear-enriched extracts with anti-
E2F1 antibody or irrelevant IgG as a negative control. E2F1 and Tip60 were revealed by 
western blotting using anti-E2F1 and anti-Tip60 antibodies respectively. (C) GST or GST-
E2F1 fusion protein was incubated with 35S-labelled in vitro translated (IVT) Tip60 in a pull-
down experiment and analysed by SDS-PAGE followed by autoradiography. 
 
Fig.2. Tip60 acetylates E2F1 
 (A,B) H358 cells were transfected with control or HA-Tip60 expression vector. (A) Anti-
acetylated lysine antibody was used to precipitate endogenous acetylated E2F1 which was 
detected by western blotting using anti-E2F1 antibody. (B) Anti-E2F1 antibody was used to 
precipitate endogenous acetylated E2F1 which was detected by western blotting using anti-
acetylated lysine antibody. The Ac-K blot was stripped and re-probed with anti-E2F1 
antibody to confirm the presence of an overlapping E2F1 band. Expression of Tip60 was 
analysed by western blotting using anti-HA antibody. (C) H358 cells were transfected with 
control siRNA (Ctl) or with siRNA raised against Tip60. Anti-acetylated lysine antibody was 
used to precipitate endogenous acetylated E2F1 which was detected by western blotting using 
anti-E2F1 antibody. Tip60 transcripts were quantified by RT /QPCR. Gapdh was used as an 
internal control. 
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Fig. 3. Lysines 120/125 of E2F1 are the prime-candidate sites for Tip60 acetylation  
(A) Shematic representation of the E2F1 fragments used for the experiments. Minimal 
acetylated domain of E2F1 is represented as a grey bar. (B) In vitro acetyltransferase assays 
with C14-Acetyl-CoA, in vitro translated Tip60 and a panel of recombinant GST-E2F1 
fragments. Acetylated proteins were resolved by 10% SDS-PAGE. (C) GST-E2F1 proteins 
mutated for two out of three lysines (K117/K120/K125) were studied for acetylation by Tip60 
as in B. Signal intensities from autoradiography and coomassie were quantified using the 
ImageJ software and the relative densitometric areas for WT and mutant forms of E2F1 were 
determined according to coomassie staining in each condition. (D) pcDNA3-HA-Tip60 was 
transfected together with wild type or mutant K120/125R E2F1 expression vector into SAOS2 
cells. Anti-acetylated lysine antibody was used to precipitate acetylated E2F1 which was 
detected by western blotting using anti-E2F1 antibody. Actin was used as a loading control. 
 
Fig. 4. Acetylation by Tip60 upregulates E2F1 protein 
(A) H358 cells were transfected with pcDNA3.1 or pcDNA3.1-HA-Tip60 expressing vectors. 
Western blotting was carried out using anti-E2F1 or anti-HA antibody. Actin was used as a 
loading control. (B) H358 cells were transfected with control siRNA (Ctl) or with siRNA 
against Tip60. Expression of endogenous E2F1 was studied by western blotting. Actin was 
used as a loading control. Neutralisation efficiency of Tip60 expression was studied by 
RT/QPCR. Gapdh was used as an internal control. (C) H358 cells were transfected with 
pcDNA3.1, pcDNA3.1-HA-Tip60 or pcDNA3.1-HA-Tip60G380 expression vectors. Western 
blotting was carried out with anti-E2F1 or anti-HA antibody. Actin was used as a loading 
control. (D) H358 cells were cotransfected with pcDNA3-E2F1 and/or pcDNA3-HA-
Tip60G380 expression vectors. Whole cell extracts were immunoprecipitated with anti-E2F1 
antibody and immunoblotted with anti-HA or anti-E2F1 antibody. Irrelevant IgG was used as 
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a negative control for immunoprecipitation. (E) SAOS2 cells were transfected with 
pcDNA3.1, pcDNA3.1-E2F1 or pcDNA3.1-E2F1K120/125R in the presence or absence of 
pcDNA3.1-HA-Tip60. Western blotting was carried out with anti-E2F1 or anti-HA antibody 
(upper panel). Actin was used as a loading control. Signal intensities of E2F1 and actin were 
quantified using the ImageJ software and the relative densitometric areas for WT and mutant 
forms of E2F1 were determined according to actin in each condition (lower panel). 
 
Fig. 5. Tip60-dependent accumulation of E2F1 by cisplatin does not promote apoptosis 
(A, B) H358 cells were exposed for the indicated times to 50µM cisplatin. Expression of 
E2F1 was studied by western blotting with anti-E2F1 antibody (A upper panel). Actin was 
used as a loading control. Signal intensities of E2F1 and actin were quantified using the 
ImageJ software and the relative densitometric areas for E2F1 were determined according to 
actin in each condition (A, lower panel). Apoptosis was evaluated by active caspase 3 
staining followed by FACS analysis (B). Data represent the mean ± S.D. of three independent 
experiments. (C) H358 cells were transfected for 48h with either control (Ctl) or PCAF 
siRNA and treated with 50µM cisplatin for an additional 24 hours. Western blotting was 
performed using anti-PCAF or anti-E2F1 antibody. Actin was used as a loading control. (D) 
H358 cells were transfected for 48h with either control (Ctl), PCAF or Tip60 siRNA and 
treated with 50µM cisplatin for an additional 24 hours. Apoptosis was evaluated by active 
caspase 3 staining followed by FACS analysis. Data represent the mean ± S.D. of three 
independent experiments. (E) H358 cells were transfected for 48h with either control (Ctl) or 
Tip60 siRNA and treated with 50µM cisplatin for an additional 24 hours. Western blotting 
was performed using anti-E2F1 antibody (left panel). Actin was used as a loading control. 
Neutralisation efficiency of Tip60 expression was studied by RT/QPCR. (right panel). Gapdh 
was used as an internal control. (F) H358 cells were transfected for 72h with either control 
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(Ctl) or Tip60 siRNA and treated with 50µM cisplatin for an additional 2 hours. Expression 
of E2F1 was studied by western blotting (upper panel). Actin was used as a loading control. 
Neutralisation efficiency of Tip60 expression was studied by RT/QPCR. (lower panel). 
Gapdh was used as an internal control. 
 
Fig. 6. Tip60 and E2F1 control ERCC1 accumulation in response to cisplatin 
(A) H358 cells were exposed for the indicated times to 50µM cisplatin. Expression of ERCC1 
was studied by western blotting with anti-ERCC1 antibody (upper panel). Actin was used as a 
loading control. Signal intensities of E2F1 and actin were quantified using the ImageJ 
software and the relative densitometric areas for ERCC1 were determined according to actin 
in each condition (lower panel). (B), H358 cells were transfected for 72h with either control 
(Ctl) or Tip60 siRNA and treated with 50µM cisplatin for an additional 2 hours. Expression 
of E2F1 and ERCC1 was studied by western blotting (upper panel). Actin was used as a 
loading control. Neutralisation efficiency of Tip60 expression was studied by RT/QPCR. 
(lower panel). Gapdh was used as an internal control. (C) H358 cells were transfected with 
HA-Tip60 expression vector for 72h and treated or not with 50µM cisplatin for an additional 
2 hours. Western blotting was performed using anti-HA or anti-ERCC1 antibody. Actin was 
used as a loading control. (D) SAOS2 cells were cotransfected with plasmids encoding wild 
type or K120/125R mutant E2F1. Protein extracts were subjected to western blotting with 
anti-E2F1 or anti-ERCC1 antibody. Actin was used as a loading control. 
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Supplementary Figure 1
A B
Tip60 does not affect the level of E2F1 transcripts. H358 cells were transfected with 
either HA-Tip60 expression vector (A) or siRNA raised against Tip60 (B). E2F1
transcripts were quantified by RT /QPCR. Gapdh was used as an internal control.
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Supplementary Figure 2 
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Cisplatin does not affect E2F1 mRNA expression. H358 cells were exposed for 
the indicated times to 50M cisplatin. Expression of E2F1 mRNA was studied by 
RT/QPCR. Gapdh was used as an internal control  
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Supplementary Figure 3 
Neutralization of p300 prevents E2F1 accumulation and apoptosis in response to 
cisplatin. 
H358 cells were transfected for 48 hours with either control (Ctl) or p300 siRNA and 
exposed to 50M cisplatin for an additional 24 hours. (A) Western blotting was 
performed using anti-E2F1 or anti-p300 antibody. Actin was used as a loading control. 
(B) Apoptosis was studied by Active Caspase 3 staining followed by FACS analysis.  
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Supplementary Figure 4 
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PCAF and p300 are not involved in ERCC1 accumulation in response to 
cisplatin. H358 cells were transfected for 72 hours with either control (Ctl), p300 (A) 
or PCAF (B)  siRNA and exposed to 50M cisplatin for an additional 2 hours. 
Western blotting was performed using anti-PCAF, anti-p300 and anti-ERCC1 
antibodies. Actin was used as a loading control  
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Supplementary Figure 5 
Cisplatin, Tip60 and E2F1 do not affect the level of ERCC1 transcripts. (A), H358 cells were 
exposed for the indicated times to cisplatin (50M). (B), H358 cells were transfected for 72h 
with control (Ctl) or Tip60 siRNAs and exposed for 2 hours to cisplatin (50M). (C) H358 cells 
were transfected for 48h with wild type or K(120/125)R mutant E2F1 and exposed for 2h to 
cisplatin (50M). In all cases, expression of ERCC1 transcripts was studied by RT/QPCR. Gapdh 
was used as an internal control.  
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